I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ECTRIMS 2021

-
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features

Oct 22 / Roche and Genentech
Watch Dr Kister discuss Vaccine Against SARS-CoV-2–Generated Immunity in Ocrelizumab-Treated Patients: Longitudinal Assessments (VIOLA): Study Design and Early Results
This video is about VIOLA (NCT04843774) is an open-label, observational study enrolling 60 patients with multiple sclerosis (MS) receiving ocrelizumab from NYU (New York City) and the University of Colorado (Denver) MS Centers. The primary objective is to examine longitudinal antibody and cellular responses to two-dose mRNA-platform COVID-19 vaccines (Pfizer-BioNTech and Moderna) in ocrelizumab-treated patients with MS over a 12-month period. The antibody and T-cell response data on 16 patients for whom pre-vaccine baseline, 4- and 12-week post vaccination timepoints are available are presented.

Sign up or login to unlock the full suite of MEDICALLY features

Oct 15 / Roche and Genentech
Vaccine Against SARS-CoV-2–Generated Immunity in Ocrelizumab-Treated Patients: Longitudinal Assessments (VIOLA): Study Design and Early Results
VIOLA (NCT04843774) is an open-label, observational study enrolling 60 patients with multiple sclerosis (MS) receiving ocrelizumab from NYU (New York City) and the University of Colorado (Denver) MS Centers. The primary objective is to examine longitudinal antibody and cellular responses to two-dose mRNA-platform COVID-19 vaccines (Pfizer-BioNTech and Moderna) in ocrelizumab-treated patients with MS over a 12-month period. The antibody and T-cell response data on 16 patients for whom pre-vaccine baseline, 4- and 12-week post vaccination timepoints are available are presented.

Sign up or login to unlock the full suite of MEDICALLY features

Oct 15 / Roche and Genentech
Antibody and T-Cell Responses to SARS CoV-2 Vaccines in Patients With MS on Ocrelizumab and Other Disease-Modifying Therapies: Preliminary Results of an Ongoing, Prospective Study
Peripheral B-cell depletion with anti-CD20 therapies attenuates humoral responses to vaccines, but less is known about cellular responses. Whether immune responses to COVID-19 vaccines differ between B-cell depleted and non-B cell depleted patients with multiple sclerosis (MS) is not known. The objective of this study was to compare humoral and T-cell responses to COVID-19 vaccines in 400 patients with MS receiving ocrelizumab vs other disease-modifying therapies at the time of vaccination.
06:00 PM
Duration 5mins Virtual
Long-term efficacy of satralizumab▼ in aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD): Results from the open-label extension periods of SAkuraSky and SAkuraStar
I. Kleiter, A. Traboulsee, J. Palace, T. Yamamura, K. Fujihara, A. Saiz, H-C. von Buedingen, D. Stokmaier, G. Klingelschmitt, J. Bennett

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
01:45 PM
Duration 60mins Virtual
The evolving landscape in neuromyelitis optica spectrum disorder (NMOSD) management
Kleiter I, Fujihara K, Greenberg B

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:33 PM
Duration 7mins Virtual
Sustained Reduction in 48-week Confirmed Disability Progression in Patients with PPMS Treated with Ocrelizumab▼ in the ORATORIO OLE: 8-year Follow-up
Wolinsky JS, Vermersch P, Hartung HP, Naismith RT, Airas L, Townsend B, Schneble HM, Overell J, Sauter A, Wang Q, Prajapati K, Kappos L

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar